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 SUMMARY  
 
Objectives: Botulinum toxin A (BTX-A) has been reported to have analgesic effects 
independent of its action on muscle tone, possibly by acting on neurogenic 
inflammation. Such mechanism may be involved in peripheral neuropathic pain.  
Methods: A possible direct analgesic effect of BTX-A pain processing was 
investigated in 29 patients with focal painful neuropathies and mechanical allodynia 
using a randomized double-blind placebo-controlled design. Patients received a one 
time intradermal administration of BTX-A (20 to 190 units) into the painful area. 
Outcome measures, evaluated at baseline, then at 4, 12 and 24 weeks, included 
average spontaneous pain intensity, quantified testing of thermal and mechanical 
perception and pain, allodynia to brushing (area, intensity), neuropathic symptoms, 
clinical global impression and quality of life.  
Results : BTX-A treatment, relative to placebo, was associated with persistent effects 
on spontaneous pain intensity from 2 weeks after the injection to 14 weeks. These 
effects correlated with the preservation of thermal sensation at baseline (p <0.05). 
BTX also improved allodynia to brush and decreased pain thresholds to cold, without 
affecting perception thresholds. There were sustained improvements in the 
proportion of responders (Number Needed to Treat for 50 % pain relief: 3.03 at 12 
weeks), neuropathic symptoms and general activity. Most patients reported pain 
during the injections, but there were no further local or systemic side effects.  
Interpretation : These results indicate for the first time that BTX-A may induce direct 
analgesic effects in patients with chronic neuropathic pain independent on its effects 
on muscle tone and suggest novel indications for BTX-A in analgesia.  
 
Key words: neuropathic pain – botulinum toxin A - double blind randomized study – 
allodynia  
Word count : abstract words 254 ; manuscript words : 3369  
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 INTRODUCTION 
 
 Botulinum toxin type A (BTX-A), a potent neurotoxin, is commonly used for the 
treatment of focal muscle hyperactivity, particularly dystonia and spasticity (1, 2) and 
the management of glandular hyperactivity, including hyperhidrosis (3). The 
beneficial effect of BTX-A in these conditions is believed to result from the blockade 
of presynaptic nerve terminals releasing acetylcholine (4,5,6). However, early in the 
use of BTX-A for dystonia, some authors noted that pain relief preceded muscle 
decontraction and exceeded what would have been expected solely as a 
consequence of muscle relaxation (4). These findings suggested that BTX-A might 
have analgesic properties independent of its myorelaxant action. Further information 
came from in vitro experiments demonstrating that BTX-A could inhibit neurogenic 
inflammation, a process that results from the sensitization of C-fiber nociceptors (7); 
the effects of BTX-A involved attenuation of the release of neurotransmitters 
including SP (8, 9), CGRP (10, 11) and glutamate (12) and inhibition of vanilloid 
receptor activity (13). Consistent with these in vitro experiments, peripheral injections 
of BTX-A reduces nociceptive behaviors in animal models of inflammatory (12, 14) 
and traumatic neuropathic pain (15, 16, 17).  
Neurogenic pain mechanisms may play a role in neuropathic pain due to 
peripheral nerve lesions (18), particularly those associated with allodynia, such as 
postherpetic neuralgia and post-traumatic/post-operative nerve lesions (18, 19, 20, 
21). These chronic pain conditions are significant causes of focal painful 
neuropathies (22, 23) and are very difficult to treat and often devastating (24, 25, 26). 
In most cases, the area involved is limited, and thus local injections of BTX-A may be 
suitable. The efficacy of BTX-A in neuropathic pain has only been suggested in small 
anecdotal case reports (27, 28, 29, 30).  
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 In the present study, we investigated for the first time the potential direct 
analgesic effects of one-time BTX-A in the painful area in patients with focal 
neuropathic pain (eg, post-traumatic/post-operative pain or postherpetic neuralgia) 
associated with allodynia using a double blind placebo controlled parallel group 
design. In order to exclude effects on muscle tone, the injections were performed 
intradermally.  
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 PATIENTS AND METHODS 
 This study was conducted at Ambroise Paré Hospital, Boulogne-Billancourt 
and was approved by local ethics committee. Patients were recruited between June 
2004 and October 2006 by means of physician referrals and provided written 
informed consent before inclusion.  
 Patients  
Consecutive patients with postherpetic neuralgia or post-traumatic/post-
operative neuropathies confirmed by appropriate clinical and paraclinical examination 
when necessary (e.g. EMG) were recruited and gave written informed consent. 
Criteria for inclusion were daily pain for at least six months (numerical score of at 
least 3 out of 10) clearly attributed to the nerve lesion, limited area of pain (not 
exceeding 60 cm2, corresponding to the maximal doses of BTX-A as indicated 
below) and mechanical allodynia in the painful area. Exclusion criteria were 
contraindication for BTX-A (i.e. diseases of the neuromuscular junction), 
hypersensitivity to the BTX-A formulation, coagulation disorders, any other painful 
condition, current major depression, a history of serious drug or alcohol abuse, 
compensation claim or litigation, and facial pain (due to potential increased side 
effects of BTX-A in this area). Concomitant analgesic medication was authorized, 
provided the dose was stable for at least 1 month before enrollment and throughout 
the study. Treatments acting on neuromuscular junctions and topical medications or 
procedural therapies (e.g. anesthetic blocks) were forbidden.  
Protocol  
 A randomised double-blind placebo-controlled parallel group design was used. 
A total of 4 visits was scheduled over 24 weeks (at baseline, and after 4, 12 and 24 
weeks). During the 7-day baseline period, all patients underwent testing for allodynia 
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 and were asked to record their pain intensity in a diary; eligible patients were then 
randomly assigned to two groups - one given the active drug and the other the 
placebo. A pharmacist prepared a concealed allocation schedule randomly assigning 
the treatments in blocks of four, to a consecutive series of numbers. The treatment 
allocation code was kept in a sealed envelope until the completion of the study.  
Treatment was administered by a neurologist not involved in the assessment. 
Aliquots of 100 units/vial Botulinum toxin A (BOTOX, Allergan) were reconstituted 
with 4 ml non preserved saline solution (0.9 %) as recommended by the 
manufacturer (concentration of 5 units BTX-A /0.2 ml) and placebo consisted of an 
equal volume of saline (9 %NaCl). The injection of BTX-A or saline was performed 
according to a procedure adapted from that used for hyperhidrosis (31) : BTX-A or 
placebo was injected intracutaneously into the skin 1.5 cm apart (0.2 ml and thus 5 
units of BTX-A per site) (Figure 1). We first mapped with a pen the exact area of 
mechanical allodynia for all patients. We then determined the number of injections so 
as to cover the whole allodynic area, without exceeding the predetermined maximum 
number of sites, which was fixed at 40 (corresponding to a dose of 200 units). 
The two solutions were limpid and indistinguishable. The injection syringes 
were prepared by the pharmacist in such a way that the physician performing the 
injection could not recognize the treatment. Patients and the investigator were blind 
to the treatments throughout the study.  
To minimize the pain due to injections, all patients received a cream 
formulation of lidocaine and prilocaine (EMLA) applied to the painful area 60 minutes 
before the injections; also a nurse administered an equimolar mix of nitrous oxide 
and oxygen (N2O/O2) via a high-concentration mask for 5 minutes before the 
beginning and throughout the procedure.  
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 Outcome measures  
 The primary outcome measure was self-reported average pain intensity from 
each morning’s record in a diary concerning the last 24 hours using the 11 point 
numerical scale (0: no pain; 10: maximal pain imaginable) of the Brief Pain Inventory 
(BPI) (32).  
Sensory deficits and pain were measured and assessed by the same 
investigator at baseline, and after 4 and 12 weeks, as in prior therapeutic trials (33, 
34). Brush-induced allodynia was evaluated by stroking the skin with a standardized 
brush (Senselab brush-0.5, Somedic, Sweden) and was considered as present if this 
evoked a clear sensation of pain. The intensity of allodynia (recorded on a 100 mm 
visual analog scale) and its area (traced on a transparent paper, then digitized for 
measurement on Canvas 6.0 software) were measured. Mechanical sensations 
(detection thresholds to non painful stimuli) and pain thresholds were measured with 
calibrated von Frey hairs (0.06 to 300 g) (Somedic AB, Sweden). Thermal sensations 
and pain thresholds (in °C) were assessed with a Somedic thermotest (Somedic AB, 
Sweden) by the method of limits, with baseline temperatures adjusted to the patient's 
skin temperature according to a procedure largely described elsewhere (35). 
Measurements obtained in the area of maximal pain were compared to those of the 
homologous contralateral side.  
Other secondary outcome measures (completed at baseline and follow-up 
visits) included: a visual analog scale rating the average pain over the last 24 hours 
on a 100-mm line; the neuropathic pain symptom inventory (NPSI) (36) rating the 
mean intensity of 10 neuropathic symptoms and their combination into 5 distinct 
dimensions during the last 24 hours on 11-point (0-10) numerical scales; the duration 
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 of spontaneous pain and number of pain paroxysms (assessed with the NPSI on 
categorical scales); six of seven items for pain interference of the BPI (with the 
exclusion of the item “ability to walk” judged irrelevant here) rated from 0 (does not 
interfere), to 10 (complete interference); the Hospital Anxiety and Depression Scale 
(HAD) (37) including 14 items scored as anxiety and depression scores (each on 21); 
subjective pain relief due to the treatment over the past week (from 0 % (no pain 
relief) to 100 % (maximal pain relief)); the patients’ overall impression of change 
(PGIC) on a 7-point scale (from very much improved to very much worse); and the 
assessment of blindedness.  
 The safety of BTX-A, particularly with regards to potential systemic side 
effects, was assessed throughout the study. Pain related to injections was rated as 
mild, moderate or severe.  
 Statistical analysis  
 Baseline clinical and demographic variables were compared by Fisher’s exact 
test or an unpaired t-test. The primary outcome measure was the change in the 
weekly averages of the daily ratings of pain on numerical scales from the baseline 
week through the 24th week of treatment. Changes in primary and secondary 
outcome measures (quantified measures of deficits and pains, pain scores, 
symptoms, quality of life, mood) expressed as differences between baseline and the 
values obtained at each time point were analyzed using a repeated measures 
analysis of variance (ANOVA) in which the factors were treatment group (BTX-A or 
placebo) and time at specified time points (ie, 4, 12 and 24 weeks, except for 
quantified measures which were not repeated at 24 weeks). Analyses of variance 
with the Bonferroni correction were used for post hoc comparisons. The Spearman 
rank correlation test was used to analyze the correlations between pairs of variables. 
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 The proportion of responders was defined as patients with   50 % reduction in 
weekly mean pain scores and Numbers Needed to Treat (NNT) were provided for 50 
% pain relief. Fisher's exact test was used to compare categorical variables. The 
intent to treat (ITT) population analysed for efficacy included all randomized patients 
who had a baseline evaluation and at least one post-baseline visit. Subjects who 
discontinued prematurely from the study were analysed in two ways : a/ Last 
observation carried forward (LOCF) : the last observation before the time of 
discontinuation was carried forward to the end of the study period from which they 
discontinued ; b/Observed data : data were regarded as missing and no values were 
imputed. For the primary and secondary end points, analysis was performed in the 
ITT population with both the LOCF approach (primary analysis) and observed data 
(additional analysis). In all cases, P values  < 0.05 were considered significant.  
 This study is registered with Clinicaltrials.gov, number NCT0057202.  
 Funding source and access to data  : The study received financial support 
from Institut National de la Santé et de la Recherche Médicale (INSERM). All the 
authors had full access to all the data in the study and they held final responsibility 
for the decision to submit for publication.  
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Results  
 
 We screened 61 consecutive patients (Figure 2), of whom 29 (19 women, 10 
men) fulfilling the inclusion criteria were randomly assigned to BTX-A or placebo 
groups. Sociodemographic variables, pain characteristics, etiology and analgesic 
treatments did not differ between the two groups (Tables 1 and 2). Seven patients 
withdrew from the study before 24 weeks (Figure 2).  
 Doses and injections  
The mean (± SD) number of injection sites was 20 ± 8 .3 for BTX-A (with 
dosages ranging from 20 to 190 units) and 19.8 ± 5.2 for the placebo. The total 
volumes of injection were also similar for BTX-A (4.4 ± 1.6) and the placebo (3.9 ± 
1.1).   
Pain intensity  
 As shown in Figure 3A, BTX-A improved weekly average pain intensity 
throughout the study in comparison with the placebo (p = 0.038, LOCF analysis) 
(Figure 3A). The improvement of pain was significant at several time points (posthoc 
analysis), starting from week 2 (p = 0.025). The effect increased therafter for up to 4 
weeks (p = 0.036), remained stable for up to 14 weeks (the mean pain scores 
decreased by 1.9 ± 1.9 with BTX-A compared to 0.3 ± 1.8 with the placebo; p = 0.03), 
then was no longer significant (LOCF approach), but remained significant in analysis 
of observed cases (p = 0.046 at 24 weeks). Higher proportions of patients were 
responders to BTX-A than to placebo (Table 2), and these proportions increased 
between 4 and 12 weeks (Figure 3B). The NNT for 50 % pain relief with BTX-A was 
3.70 (2.04-23.2) at 4 weeks and 3.03 (1.64-21.6) at 12 weeks. One patient treated 
with BTX-A became pain-free after 12 weeks (no patient was pain-free with the 
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placebo) (Table 2).  
 Effects on quantified measures of perception and pain  
 The area and intensity of allodynia to brush and cold pain thresholds on the 
painful side were reduced in the group treated with BTX-A (Figure 4). There was no 
effect on thresholds to non painful thermal and mechanical stimuli or on heat and 
mechanical pain thresholds on either side (not shown). 
 Other outcomes  
BTX-A significantly improved average pain intensity assessed at each follow 
up visit (p = 0.0073, repeated measures ANOVA) and provided global pain relief 
(Table 3). After 12 weeks, 40 % of patients receiving BTX-A (and 14 % with the 
placebo) rated themselves as much or very much improved, 53 % were unchanged 
or worse (78 % with the placebo) and 7 % minimally improved (7 % with the 
placebo). Three dimensions of the NPSI (burning, paroxysmal pain, allodynia) 
corresponding to 5 neuropathic symptoms, improved in the BTX-A group while other 
dimensions (deep pain, paresthesia/dysesthesia) were unaffected (Table 3). The 
number of pain paroxysms was also reduced (p = 0.05 at 4 weeks ; p = 0.042 at 12 
weeks ; p = 0.039 at 24 weeks), although pain duration was unaffected. BTX-A also 
improved some markers of quality of life including general activity and mood (Table 
3). The effect of BTX-A on general activity correlated with the improvement of 
average pain intensity (Rho : 0.71; p = 0.008 at 4 weeks; Rho : 0.43; p = 0.02 at 12 
weeks). Anxiety scores of the HAD slightly improved in the BTX-A group but tended 
to worsen in the placebo group while the depression scores remained unchanged 
(Table 3).  
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Exploratory analysis of the predictive factors for BTX-A analgesic effects  
The effects of BTX-A on average pain intensity did not differ between sexes 
and did not correlate with the age, duration or intensity of pain or neuropathic 
symptoms. However, they were inversely correlated with the magnitude of thermal 
deficits on the painful side at baseline (Figure 3C). Similar inverse correlations were 
observed regarding burning pain (Rho : -0.83 at 4 weeks ; p = 0.018; Rho = -0.80 at 
12 weeks ; p = 0.003 and Rho : –0.79 at 24 weeks ; p = 0.008) and brush evoked 
pain (Rho : -0.66 at 12 weeks ; p = 0.018; Rho : -0.59 at 24 weeks ; p = 0.048). This 
suggested that the better the thermal sensation at baseline was preserved, the better 
the analgesic effects of BTX-A.  
Study safety and assessment of blindedness  
Most patients reported that the injections were painful, with no difference 
between BTX-A (mild pain: 7, moderate pain: 4, severe pain: 2) and placebo (mild 
pain: 6, moderate pain: 4, severe pain: 2) groups. The severity of pain was related to 
the site of injection, being greater when at the hands or elbow. No other local or 
systemic side effects were reported during the injection or at any other time during 
the study. Seven patients experienced mild side effects associated with the 
anesthetic procedure (euphoria: 3 patients with placebo, 3 with BTX-A; anxiety: 1 
patient with BTX-A).  
No patient was able to recognize the active treatment from side effects and 
seven patients (five with BTX-A) thought they had received BTX-A because of 
improvement. The other patients were unable to state which drug they had received.  
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Discussion  
 
The present study aimed to investigate the potential direct analgesic effects of 
BTXA in patients with focal neuropathic pain using a randomized, double-blind, 
placebo-controlled design. Our main findings showed that one-time intradermal 
injections of BTX-A induce long-lasting analgesic effects counteracting focal chronic 
neuropathic pain. These effects involved self-assessment of pain and clinician-based 
quantified measures. In particular we observed a reduction of the intensity and area 
of mechanical allodynia and a decrease in cold pain thresholds on the painful side, 
while perception thresholds were not modified. These features indicate that BTX-A 
has selective effects on pathological pain processing. Moreover several neuropathic 
symptoms and some measures of quality of life improved. Our data indicate new 
potential mechanisms of BTX-A in analgesia. They also suggest novel therapeutic 
indications for BTXA.  
In the present study, we found that the preservation of thermal sensibility at 
baseline was correlated with the analgesic effects of BTX-A, e.g. patients with less 
impaired sensory deficits were better responders. This observation is in keeping with 
recent preclinical data, showing that BTX-A blocks the protein kinase C potentiation 
of Transient Receptor Potential Vanilloid 1 (TRPV1), a capsaicin and heat sensitive 
ion channel expressed in nociceptors, that participates in the transduction of thermal 
stimuli by sensory nerve endings (13). It is thus possible that BTX-A acts on 
sensitized nociceptive fibers to produce its analgesic effects. This mechanism could 
also account for the early effect of BTX on pain observed here, as soon as week 2 
after the injection. In keeping with our results, recent studies using models of 
experimental pain in healthy subjects showed that BTX-A reduces capsaicin-evoked 
pain and neurogenic vasodilatation in human skin (38, 39). However, several other 
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studies using various experimental models of pain (40, 41, 42, 43, 44) yielded 
negative results. Several reasons may account for these discrepancies, including the 
use of different preparations of BTX, which are not bioequivalent (45) and the 
application of different experimental stimuli. However, the main reason may be that 
the binding of BTX to its protein receptors (46), the key step for its analgesic effects, 
is probably greater in chronic pathological pain than in acute experimental pain. It is 
thus difficult to translate data from experimental pain in healthy volunteers to 
sustained pathological pain (5, 6, 47). In any case, a possible central target for the 
action for BTX-A cannot be ruled out (4), particularly since several of our patients 
showed improved relief over time after one-time administration. Work in animals and 
humans is necessary to elucidate the mechanisms of the analgesic effects of BTX-A 
in neuropathic pain.  
BTX is generally administered as intramuscular injection for focal spasticity or 
dystonia (1, 2). Since our patients presented with superficial pain and allodynia, and 
in order to exclude possible secondary effects of BTX on muscle tone, we used 
intradermal injections of BTX, matched to the extent of the painful area, according to 
a procedure recommended for hyperhidrosis (3, 31). This procedure was safe and 
relevant for our patients, although it may only be suitable for patients with focal 
neuropathies, where the extent of pain is limited. It remains to be established 
whether this mode of administration can also be used for patients with larger areas of 
pain, such as those with painful polyneuropathies.  
Neuropathic pain is a common chronic pain condition affecting up to 7-8 % of 
the general population (48, 49) with a devastating impact on quality of life and 
substantial socioeconomic costs (50, 51). First-line treatments include antiepileptics 
or antidepressants (24, 25, 52). However, these treatments have limited 
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effectiveness: they reduce pain more than placebo in less than 30 % of patients and 
are relatively frequently associated with side effects (24, 25). Topical analgesics such 
as lidocaine patches or capsaicin may be proposed, particularly for focal 
neuropathies, but their efficacy is modest (24). BTX-A appears to have significant 
advantages over existing treatments, at least on the basis of the present study which 
included a highly selective group of patients with allodynia. One is the extended 
duration of its analgesic effects despite a one-time administration, with several 
patients still reporting improvement at 24 weeks. The efficacy of BTX-A also seems 
to compare favorably with that of other treatments, with a NNT for 50 % pain relief of 
3 at 12 weeks. Finally, the drug was very well tolerated: the only notable side-effect 
was moderate to severe transient pain during injections in several patients especially 
when involving the fingers, despite a pretreatment with local anesthetics and 
administration of nitrous oxide. However, this problem could be overcome with other 
modes of analgesia, including peripheral nerve blocks, intravenous propofol or 
lidocaine reconstructed BTX, as used for hyperhidrosis (53). Large scale studies are 
needed to confirm these results and determine whether BTX-A may also be effective 
in other forms of neuropathic pain.  
We conclude that intradermal injection of BTX-A has direct analgesic effects in 
patients with focal chronic neuropathic pain associated with allodynia. It is suggested 
that the observed analgesia may due to a local peripheral effect of BTXA on 
nociceptive fibers, although subsequent central effects are possible. The treatment 
was particularly well tolerated. These data suggest that BTXA should be considered 
as part of the therapeutic arsenal against focal neuropathic states.  
Conflicts of interest : DR, NA, DB and FM declare no conflicts of interest related to the study.  
Aknowledgements : We are indepted to S. Donnadieu, MD, E. Le Viet, MD, and C. Mathoulin, 
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Figure 1 :  
Photograph showing the BTX-A intradermal injection technique for the painful area in 
one male patient with post-traumatic radial nerve lesion just before BTX-A injection. 
Intradermal injections were performed using equidistant grid lines 1.5 cm apart 
(marked in black) aiming to cover the area of maximal spontaneous pain (in blue) 
and the whole area of allodynia (in red). The same procedure was used in patients 
with irregular areas of allodynia, except that the grid lines were sometimes 
incomplete in remote angles.  
 
Figure 2:  
Study flow chart  
 
Figure 3  
A: Effects of BTX-A and the placebo on weekly mean pain scores (ITT patients) from 
1 to 24 weeks.  
* P < 0.05 versus placebo (post-hoc analyses of variance).  
B Proportions of responders to BTX-A and the placebo (   50 % pain relief on the 
basis of weekly mean pain scores) after 4, 12 and 24 weeks. There was no 
responder to the placebo at 4 weeks.  
* P < 0.05 versus placebo  
C: Correlation between the baseline severity of thermal deficits (expressed as the 
difference between warm and cold detection thresholds on the painful side) and the 
effects of BTX-A on weekly average pain intensity assessed from pain diaries at 12 
weeks (expressed as the difference between pain intensity at baseline and 12 
weeks). Rho: -0.69; p = 0.009. Similar correlations were found with pain intensity at 4 
weeks (Rho: -0.63; p = 0.02) and at 24 weeks (Rho: - 0.58; p = 0.03).  
 
Figure 4 :  
Effects of BTX-A and the placebo after 4 and 12 weeks on (A) average intensity of 
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allodynia to brush (rated on a 0-100 mm visual analog scale); (B) mean area of 
allodynia to brush (in cm 2); and (C) cold pain thresholds on the painful side. 
Compared to the placebo, BTX-A attenuated the intensity (p = 0.050) and area of 
allodynia to brush (p = 0.03) and reduced cold pain thresholds on the painful side 
without affecting cold pain thresholds on the normal side, consistent with an effect on 
cold allodynia (p = 0.029) (repeated measures ANOVA at 4 and 12 weeks).  
* P < 0.05 compared to the placebo (posthoc analyses) 
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Table 1 : Patients’ characteristics and baseline values.  
 BTX-A 
n = 15 
Placebo  
n = 14 
Characteristics  
Age (years) (± SD) (min-max) 
Sex, N (women/men) 
Pain duration (months ± SD) (min-max) 
Baseline weekly pain intensity (mean ± SD)  
Etiologies of pain (N)  
-post-traumatic/post-operative  
- postherpetic neuralgia  
Site of maximal pain (N) 
- hand 
- foot 
- trunk 
- pelvis 
- elbow  
Concomitant treatment (N)  
(some patients were taking > 1) 
None  
Weak analgesics/anti-inflammatories 
Opioid analgesics  
Tricyclic antidepressants  
Antiepileptics  
Benzodiazepines  
 
53.8 ± 13.9 (31-78) 
9/6 
49.2 ± 31.3 (6-108) 
6.3± 1.8 
 
12 
3 
 
5 
3 
4 
2 
1 
 
 
5 
2 
4 
3 
4 
4 
 
49.7 ± 15.9 (27-76) 
10/4 
50.2 ± 66.1 (12-264) 
5.9±2.0 
 
13 
1 
 
7 
3 
1 
2 
1 
 
 
4 
3 
6 
4 
4 
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Table 2 : Individual baseline characteristics of the patients included in the study (n = 29) and 
responses to treatment.  
Patients 
n°  
Age 
(years) 
Sex  
(F/M) 
 
Pain 
duration   
(months) 
Aetiology of the nerve lesion  Treatment   % reduction 
in pain (week 
12)1 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
53 
67 
78 
45 
51 
27 
55 
73 
76 
45 
31 
39 
44 
51 
40 
57 
38 
75 
69 
75 
44 
54 
32 
51 
46 
58 
29 
54 
46 
F 
M 
F 
F 
F 
F 
F 
F 
M 
M 
M 
M 
M 
F 
F 
F 
M 
F 
F 
F 
F 
M 
F 
F 
M 
F 
F 
M 
F 
12 
48 
24 
72 
36 
24 
48 
24 
84 
72 
96 
12 
84 
36 
24 
36 
12 
48 
24 
60 
24 
18 
12 
24 
84 
24 
264 
6 
108 
Postsurgical (radial nerve) 
Postsurgical (sural biopsy) 
Postherpetic neuralgia2 
Trauma (musculocutaneous nerve) 
Postherpetic neuralgia (thoracic) 
Trauma (peroneal nerve)  
Postsurgical (post-thoracotomy) 
Postsurgical (herniorrhaphy)3 
Postherpetic neuralgia  
Trauma (radial nerve)  
Trauma (sural nerve) 
Postsurgical (carpal tunnel syndrome) 
Postsurgical (carpal tunnel syndrome) 
Postsurgical (carpal tunnel syndrome) 
Trauma (median nerve) 
Postsurgical (carpal tunnel syndrome) 
Trauma (ulnar nerve)  
Postherpetic neuralgia  
Trauma (peroneal nerve)  
Postsurgical (carpal tunnel syndrome) 
Postsurgical (carpal tunnel syndrome) 
Postsurgical (ulnar nerve transposition) 
Postsurgical (herniorrhaphy)4 
Postsurgical (carpal tunnel syndrome) 
Trauma (radial nerve)  
Postsurgical (carpal tunnel syndrome) 
Postsurgical (ulnar nerve transposition)  
Postsurgical (herniorrhaphy) 1 
Postsurgical (hysterectomy)2 
placebo 
BTX-A 
BTX-A 
placebo 
BTX-A 
placebo 
BTX-A 
placebo 
placebo 
placebo 
BTX-A 
BTX-A 
BTX-A 
BTX-A 
placebo 
placebo 
placebo 
BTX-A 
placebo 
BTX-A 
BTX-A 
placebo 
placebo 
BTX-A 
BTX-A 
placebo 
placebo 
BTX-A 
BTX-A 
-11 
50 
16 
46 
72 
23 
50 
36 
-21 
-50 
38 
4 
59 
15 
58 
36 
-9 
16 
8 
-9 
-8 
-12 
-52 
13 
51 
1 
-7 
100 
42 
1
 The percent reduction in pain at week 12 was calculated according to the following formula 
: 100- (pain score at week 12/baseline score x100). Negative values correspond to an 
increase in pain and positive values correspond to a decrease in pain. In one patient (n°20) 
who stopped the study before week 12, the value obtained at the last follow up visit (week 4) 
was taken into account. One patient (n°28) had a total pain relief (100 % pain reduction).  
2 Postherpetic neuralgia involved the trunk in all cases.  
3
 Lesion of the ilioinguinal nerve  
4  Lesion of the iliohypogastric nerve  
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Treatment  BTX-A  Placebo  
Time period  Baseline  Week 4  Week 12 Week 24 Baseline  Week 4  Week 12 Week 24 
Mean pain (VAS) (± SD) 
 
Pain relief (0-100 %) ( ± SD) 
 
NPSI symptoms (mean ± SD) 
Burning (0-10) 
Squeezing (0-10) 
Pressure (0-10) 
Electric shocks (0-10) 
Stabbing (0-10) 
Evoked pain to brush (0-10) 
Evoked pain to pressure(0-10) 
Evoked pain to cold (0-10) 
Tingling (0-10) 
Pins and needles (0-10) 
 
BPI-Interference (mean ± SD) 
General activity (0-10) 
Sleep (0-10) 
Mood (0-10) 
Normal work (0-10) 
Social relations (0-10) 
Enjoyment of life (0-10) 
 
HAD score (mean ± SD)  
Anxiety score 
Depression score  
68.6 ± 15.3 
 
 
 
5.7 ± 3.3 
3.7 ± 3.3 
4.5 ± 3.8 
6.5 ± 3.1 
5.5 ± 3.7 
8.0 ± 1.6 
8.4 ± 1.6 
5.3 ± 4.3 
4.5 ± 4.4 
6.5 ± 4.6 
 
 
6.0 ± 2.6 
4.7 ± 3.5 
3.9 ± 3.9 
5.9 ± 3.0 
3.0 ± 3.2 
2.7 ± 2.7 
 
 
9.7 ± 5.6 
8.8 ± 3.8 
45.0 ± 30.0* 
 
28.6 ± 37.5 
 
3.7 ± 3.2* 
2.8 ± 3.1 
3.8 ± 3.1 
4.1 ± 3.4* 
2.9 ± 3.3* 
5.4 ± 3.3* 
5.7 ± 3.0 
3.3 ± 3.6 
4.2 ± 3.6 
4.2 ± 3.6 
 
 
4.2 ± 2.6* 
2.9 ± 2.7 
3.4 ± 2.8 
4.7 ± 2.7 
2.3 ± 2.9 
2.3 ± 2.8 
 
 
8.0 ± 4.6* 
7.5 ± 3.7 
40.3 ± 27.3* 
 
33.3 ± 40.9* 
 
3.4 ±3 .7* 
3.1 ± 3.5 
4.1 ± 3.6 
4.3 ± 3.7* 
4.0 ± 3.3 
5.0 ± 3.2* 
5.9 ± 2.9 
2.5 ± 3.2* 
3.4 ± 3.7 
4.1 ± 3.5 
 
 
3.6 ± 2.9* 
2.8 ± 3.3 
2.2 ± 2.3* 
4.9 ± 2.5 
2.2 ± 2.6 
2.1 ± 2.8 
 
 
8.0 ± 3.9* 
8.4 ± 4.3 
47.9 ± 28.8* 
 
25.3 ± 36.0 
 
3.9 ± 3.8 
3.5 ± 3.7 
4.0 ± 3.5 
4.7 ± 3.7 
3.9 ± 4.0 
6.0 ± 3.1 
6.3 ± 2.9 
3.3 ± 3.5 
3.9 ± 3.7 
4.7 ± 3.6 
 
 
4.3 ± 2.9 
3.2 ± 3.6 
3.2 ± 3.1 
5.3 ± 3.4 
2.7 ± 3.6 
2.4 ± 3.7 
 
 
8.1 ± 5.6 
8.1 ± 4.4 
60.0 ± 18.9 
 
 
 
4.7 ± 3.3 
4.2 ± 3.3 
4.0 ± 3.0 
5.9 ± 3.3 
5.0 ± 3.7 
7.8 ± 2.0 
8.0 ± 2.0 
5.2 ± 3.4 
4.6 ± 3.4 
5.6 ± 3.4 
 
 
5.6 ± 2.6 
5.4 ± 2.4 
4.0 ± 2.7 
6.3 ± 2.7 
2.6 ± 2.0 
2.6 ± 2.4 
 
 
9.2 ± 4.7 
7.7 ± 3.2 
54.0 ± 22.0 
 
10.0 ±16.7 
 
4.6 ± 3.0 
2.7 ± 3.4 
3.0 ± 3.0 
5.8 ± 3.3 
4.9 ± 3.5 
6.8 ± 2.6 
6.5 ± 3.3 
4.1 ± 3.0 
3.9 ± 2.8 
4.9 ± 2.8 
 
 
5.4 ± 2.7 
4.7 ± 3.2 
4.4 ± 2.9 
5.6 ± 2.8 
2.9 ± 2.0 
3.1 ± 3.3 
 
 
11.1 ± 4.6 
7.2 ± 3.8 
56.4 ± 26.4 
 
7.7 ± 14.8 
 
5.1 ± 3.3 
1.7 ± 2.7 
2.4 ± 2.8 
5.7 ± 2.9 
5.1 ± 3.9 
7.1 ± 2.9 
7.1 ± 2.8 
5.6 ± 3.7 
4.5 ± 3.2 
5.6 ± 3.5 
 
 
5.4 ± 2.6 
3.6 ± 3.3 
4.6 ± 3.2 
5.7 ± 2.7 
3.1 ± 2.4 
3.0 ± 3.3 
 
 
10.2 ± 4.2 
8.3 ± 3.7 
58.5 ± 26.3 
 
7.6 ± 15.8 
 
4.6 ± 3.3 
4.1 ± 2.7 
3.5 ± 2.9 
5.7 ± 3.0 
4.9 ± 3.4 
7.0 ± 3.7 
7.1 ± 2.7 
5.5 ± 3.5 
4.2 ± 3.6 
5.5 ± 3.6 
 
 
5.3 ± 2.6 
4.8 ± 2.9 
4.8 ± 2.7 
5.2 ± 2.3 
2.3 ± 1.8 
2.3 ± 3.0 
 
 
10.3 ± 4.8 
8.2 ± 3.9 
 
Table 3:  Comparison of the effects of BTX-A or placebo on average pain intensity (VAS), pain relief, neuropathic symptoms of the Neuropathic Pain Symptom 
Inventory (NPSI), 6 items of the Brief Pain Inventory interference (BPI) scores, and anxiety and depression scores of the Hospital Depression and Anxiety 
(HAD) scale. Data are presented for ITT patients (LOCF analysis). * p < 0.05 versus placebo. Effects on burning and electric shocks were significant at 24 
weeks in analysis of observed data (p<0.05).  
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